- FDA会在2026年12月31日前将BPC-157重新归类至《散装药物物质清单》的第1类吗？14¢14%
The FDA’s Pharmacy Compounding Advisory Committee voted narrowly in July 2026 to recommend BPC-157 for the 503A Bulks List despite staff findings of insufficient safety and efficacy data, creating momentum for potential interim relief. BPC-157 was removed from Category 2 enforcement-risk status in April 2026 after nominators withdrew, but it has not entered Category 1 or gained compounding authorization. In mid-October 2026, HHS and FDA submitted an interim access policy covering certain peptides including BPC-157 to the White House Office of Management and Budget for review, which could establish temporary enforcement discretion while permanent rulemaking proceeds. Any final shift requires formal FDA action and notice-and-comment procedures that typically span months; traders are monitoring the outcome of the current White House review and subsequent agency steps for signals on timeline.
规则
如果食品药品监督管理局（FDA）在指定日期 23:59 ET 前宣布已将或将把 BPC-157 重新分类至《散装药物成分清单》的第 1 类，则本市场判定为“是”。否则，此市场将判定为“否”。 符合条件的公告必须是官方且公开的。任何传闻或非公开的意向声明均不符合条件。 任何宣布该药物已重新分类至第 1 类的公告均符合条件。在本市场期限内，任何表示未来有意将该药物重新分类至第 1 类的公告均符合条件，无论截至指定日期是否已完成重新分类。 符合条件的重新分类必须是重新分类至《散装药物成分清单》的第 1 类，或重新分类至允许临时调配该药物的同等分类。从其他类别中移除不符合条件。 本市场的判定依据为 FDA 的官方声明；不过，也会参考可信报道形成的共识。
机器翻译。如有争议，以原文为准。